MDL-811 treatment led to strong tumor regression in both PDX models (Figure 3D), with decreased Ki67 staining and reduced SIRT6-specific histone H3 acetylation marks (Figure 3, E and F), consistent with the pharmacological effect of MDL-811 in the CDX model. This evidence concerns the gene SIRT6 and neoplasm.